Compare Novavax Inc (NVAX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Upwork Inc — how do they compare? Novavax Inc trades at $9.86 (market cap $1.68B), while Upwork Inc trades at $8.24 (market cap $1.04B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | UPWK | |
|---|---|---|
Market Cap | $1.68B | $1.04B |
Sector | Health | Industrials |
52-Week High | $11.19 | $22.11 |
52-Week Low | $6.22 | $7.84 |
Enterprise Value | $1.26B | $802.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Upwork (UPWK) trades at $8.32, down 5.35% amid bearish technical signals and recent earnings volatility. The stock shows mixed fundamentals with strong gross margins of 77.21% but declining net income margins from 28.02% in 2024 to 14.65% in 2025. Recent Q2 2026 earnings beat expectations but weak guidance triggered a selloff. Analyst consensus remains positive with a $9.00 price target despite ongoing securities fraud investigations.
The stock presents a value opportunity with low P/E of 10.67 and P/S of 1.44, but faces significant headwinds from AI disruption to freelance demand and multiple legal investigations. Near-term performance depends on management's ability to navigate AI transition while maintaining client growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
